Risk of prostate cancer and thrombosis‑related factor polymorphisms

Ghasemi,Somayehsadat; Tavakoli,Aydin; Moghadam,Mohamad; Zargar,Mohamad  Ali; Abbaspour,Maryam; Hatamnejadian,Nasim; Ebrahimi,Ahmad

doi:10.3892/br.2013.180

Risk of prostate cancer and thrombosis‑related factor polymorphisms

Authors:
- Somayehsadat Ghasemi
- Aydin Tavakoli
- Mohamad Moghadam
- Mohamad Ali Zargar
- Maryam Abbaspour
- Nasim Hatamnejadian
- Ahmad Ebrahimi
View Affiliations

Affiliations: Parseh Medical Genetics Counseling Center, Tehran, Islamic Republic of Iran, Hematology Research Center, Shiraz University of Medical Science, Shiraz, Islamic Republic of Iran, Hasheminejad Kidney Center, Tehran, Islamic Republic of Iran, Cellular and Molecular Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran
Published online on: October 4, 2013 https://doi.org/10.3892/br.2013.180
Pages: 53-56

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Venous thromboembolism (VTE) is a complication commonly encountered in cancer patients and is considered to be a major cause of morbidity and mortality. The genetic polymorphisms of thrombophilic factors in cancer patients have been focused on during the last few years. However, the number of available studies on the association between prostate cancer and thromboembolic diseases is limited. Prostate cancer is one of the four major types of cancer and its development is affected by a variety of environmental and genetic factors. In the present study we aimed to focus on the effects of thromboembolic factor gene variations on the risk of prostate cancer. In order to conduct our prospective study, we used amplification‑refractory mutation system‑polymerase chain reaction to investigate three polymorphisms [factor V Leiden (FVL) G1691A, factor II (prothrombin, PTH) G20210A and methylenetetrahydrofolate reductase (MTHFR) C677T] in prostate cancer patients, via comparison with normal individuals. The results demonstrated no significant differences in FvL and PTH gene variations between cases and controls (P>0.05). Although some cases with the T allele of MTHFR 677 were identified, no significant solidarity was established by statistical analysis (P>0.05). Therefore, non‑genetic factors that may disturb homeostatic balance should also be considered in future studies, in order to determine the exact association between VTE and prostate cancer.

View Figures

View References

1	Vairaktaris E, Yapijakis C, Wiltfang J, et al: Are factor V and prothrombin mutations associated with increased risk of oral cancer? Anticancer Res. 25:2561–2565. 2005.PubMed/NCBI
2	Van Hemelrijck M, Adolfsson J, Garmo H, et al: Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol. 11:450–458. 2010.
3	Trikha M and Nakada MT: Platelets and cancer: implications for antiangiogenic therapy. Semin Thromb Hemost. 28:39–44. 2002. View Article : Google Scholar : PubMed/NCBI
4	Baade PD, Youlden DR and Krnjacki LJ: International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res. 53:171–184. 2009. View Article : Google Scholar : PubMed/NCBI
5	Zeegers MP, Jellema A and Ostrer H: Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer. 97:1894–1903. 2003. View Article : Google Scholar : PubMed/NCBI
6	Eeles RA, Kote-Jarai Z, Giles GG, et al: Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 40:316–321. 2008. View Article : Google Scholar : PubMed/NCBI
7	Ramacciotti E, Wolosker N, Puech-Leao P, et al: Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb Res. 109:171–174. 2003. View Article : Google Scholar : PubMed/NCBI
8	Eroglu A, Egin Y, Cam R and Akar N: The 19-bp deletion of dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR) C677T, factor V Leiden, prothrombin G20210A polymorphisms in cancer patients with and without thrombosis. Ann Hematol. 88:73–76. 2009. View Article : Google Scholar
9	Ozkan M, Sivgin S, Kocyigit I, et al: Do thrombophilic gene mutations have a role on thromboembolic events in cancer patients? Asia Pac J Clin Oncol. 8:e34–e41. 2012. View Article : Google Scholar : PubMed/NCBI
10	Pectasides D, Pectasides E, Papaxoinis G, et al: Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience. Anticancer Res. 29:769–775. 2009.
11	Bourdoumis A, Papatsoris AG, Chrisofos M, Efstathiou E, Skolarikos A and Deliveliotis C: The novel prostate cancer antigen 3 (PCA3) biomarker. Int Braz J Urol. 36:665–669. 2010. View Article : Google Scholar : PubMed/NCBI
12	Hansel DE, DeMarzo AM, Platz EA, et al: Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies. J Urol. 177:1736–1740. 2007. View Article : Google Scholar : PubMed/NCBI
13	Kennedy DA, Stern SJ, Matok I, et al: Folate intake, MTHFR polymorphisms, and the risk of colorectal cancer: a systematic review and meta-analysis. J Cancer Epidemiol. 2012:9525082012.PubMed/NCBI
14	Ozdemir S, Silan F, Hasbek Z, et al: Increased T-allele frequency of 677 C>T polymorphism in the methylenetetrahydrofolate reductase gene in differentiated thyroid carcinoma. Genet Test Mol Biomarkers. 16:780–784. 2012.
15	Izmirli M, Inandiklioglu N, Abat D, et al: MTHFR gene polymorphisms in bladder cancer in the Turkish population. Asian Pac J Cancer Prev. 12:1833–1835. 2011.PubMed/NCBI
16	Jakubowska A, Rozkrut D, Antoniou A, et al: Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. Br J Cancer. 106:2016–2024. 2012.
17	Kang BS, Ahn DH, Kim NK and Kim JW: Relationship between metabolic syndrome and MTHFR polymorphism in colorectal cancer. J Korean Soc Coloproctol. 27:78–82. 2011. View Article : Google Scholar : PubMed/NCBI
18	Shannon B, Gnanasampanthan S, Beilby J and Iacopetta B: A polymorphism in the methylenetetrahydrofolate reductase gene predisposes to colorectal cancers with microsatellite instability. Gut. 50:520–524. 2002. View Article : Google Scholar : PubMed/NCBI
19	Vossen CY, Hoffmeister M, Chang-Claude JC, Rosendaal FR and Brenner H: Clotting factor gene polymorphisms and colorectal cancer risk. J Clin Oncol. 29:1722–1727. 2011. View Article : Google Scholar : PubMed/NCBI
20	Pihusch R, Danzl G, Scholz M, et al: Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer. 94:3120–3126. 2002. View Article : Google Scholar : PubMed/NCBI
21	Arslan S, Manduz S, Epozturk K, Karahan O and Akkurt I: Association of deep venous thrombosis with prothrombotic gene polymorphism identified in lung cancer cases. Mol Biol Rep. 38:2395–2400. 2011. View Article : Google Scholar : PubMed/NCBI